What question did this study set out to answer?

To assess outcomes of stage 0+ lower gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

December 8, 2025BloodOpen Access

Stage 0+ lower gastrointestinal (LGI) acute graft-versus-host disease (aGVHD) is associated with high response to non-systemic treatment, low incidence of moderate to severe chronic graft-versus-host disease (cGVHD) and low non-relapse mortality (NRM)

View Full Paper

Ask AI

Bookmark

Authors

Evaluation reveals acute graft-versus-host disease treatment response in stage 0+ patients, suggesting effective management with topical treatment.

To assess outcomes of stage 0+ lower gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Evaluated 376 adults who underwent alloHCT.
Stratified patients by GVHD assessment at day 100: no aGVHD, no LGI aGVHD, stage 0+, and stages 1-4.
Analyzed treatment response using cumulative incidence function and Kaplan-Meier method.
Overall day 28 GVHD treatment response was 92% in stage 0+ compared to 78% in stages 1-4.
Low incidence of moderate to severe cGVHD (8%) and non-relapse mortality (4%) in stage 0+.
Most stage 0+ patients were treated with topical budesonide, achieving high treatment response.

Ovalle et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Evaluation reveals acute graft-versus-host disease treatment response in stage 0+ patients, suggesting effective management with topical treatment.

To assess outcomes of stage 0+ lower gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Evaluated 376 adults who underwent alloHCT.
Stratified patients by GVHD assessment at day 100: no aGVHD, no LGI aGVHD, stage 0+, and stages 1-4.
Analyzed treatment response using cumulative incidence function and Kaplan-Meier method.
Overall day 28 GVHD treatment response was 92% in stage 0+ compared to 78% in stages 1-4.
Low incidence of moderate to severe cGVHD (8%) and non-relapse mortality (4%) in stage 0+.
Most stage 0+ patients were treated with topical budesonide, achieving high treatment response.

Ovalle et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark